Deals Shaping The Medical Industry, September 2020
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
You may also be interested in...
CMOs Face Capacity Challenges, Talent Shortages As Pandemic Increases Demand For Their Services
The need for more plant capacity, process scale-up and skilled workers are major challenges cited by a CMO in producing clinical trial materials for COVID-19 vaccines. Recent white paper says 70% of manufacturers expect to outsource activities due to pandemic.
Avistone Wins China Approval For First C-Met Inhibitor In Glioblastoma
A China green light for domestic firm Avistone's c-Met inhibitor was based on positive outcomes from the Phase II/III FUGEN study in Chinese patients with recurrent relapsing glioma with the rare PTPRZ1-MET fusion gene. Avistone’s overseas partner Apollomics is also studying the molecule in a Phase II program outside China.
Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?
The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits. Scrip takes a look at the likely impact.
| Table |
|---|